AmpliPhi makes Philip Young CEO
This article was originally published in Scrip
AmpliPhi Biosciences, a developer of bacteriophage-based antibacterial therapies, has appointed Philip Young president and CEO. Mr Young was formerly president and CEO of Osteologix, and is still on its board of directors. Edward Cappabianca, AmpliPhi's last CEO, has left the company and the board of directors to pursue other interests.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.